Academician Xu Zhang: Advancing Surgery and Systemic Therapy in Parallel—China’s Comprehensive Management of Urologic Cancers Moves to the Global Forefront

Academician Xu Zhang: Advancing Surgery and Systemic Therapy in Parallel—China’s Comprehensive Management of Urologic Cancers Moves to the Global Forefront

2026.01.12
The 9th West China Urologic Oncology Tianfu Academic Conference and the 11th Annual Academic Meeting on Urologic and Male Genitourinary Tumors of the Sichuan Anti-Cancer Association were recently held successfully in Chengdu, Sichuan. Centered on urologic and male genitourinary malignancies, the conference emphasized timeliness and diversity, combining a global perspective with Chinese clinical realities to build a high-level platform for academic exchange and innovation in urologic oncology. During the meeting, Oncology Frontier – Urology Frontier invited Academician Xu Zhang from The Third Medical Center, Chinese PLA General Hospital to share his insights on China’s distinctive achievements in minimally invasive surgery, recent advances in systemic therapy, and their clinical value.
Professor Brian Rini: From Transcriptomic Signatures to KIM-1—Breakthroughs in Precision Therapy for Renal Cell Carcinoma | 15th Shanghai Academic Conference on Urologic Oncology

Professor Brian Rini: From Transcriptomic Signatures to KIM-1—Breakthroughs in Precision Therapy for Renal Cell Carcinoma | 15th Shanghai Academic Conference on Urologic Oncology

2026.01.12
From VEGF-targeted agents to immune-based combinations and novel HIF-2α inhibitors, the expanding therapeutic arsenal for renal cell carcinoma (RCC) has significantly prolonged patient survival. At the same time, it has posed a more demanding challenge for clinicians: how to tailor the optimal treatment for each individual patient and truly achieve precision medicine.
Professor Stephen J. Freedland: The EMBARK Study Opens a New Chapter of Intensified Therapy for High-Risk BCR Prostate Cancer

Professor Stephen J. Freedland: The EMBARK Study Opens a New Chapter of Intensified Therapy for High-Risk BCR Prostate Cancer

2026.01.12
In the treatment pathway of prostate cancer, biochemical recurrence (BCR) represents a critical turning point. Especially for high-risk BCR patients with a short PSA doubling time, how to delay disease progression and improve overall survival (OS) has long been a major clinical concern. At the recent 15th Shanghai Urological Oncology Academic Conference, Oncology Frontier – UroStream invited Professor Stephen J. Freedland from Cedars-Sinai Medical Center to provide an in-depth interpretation of the EMBARK study, including its study rationale, clinical benefits, and individualized treatment strategies for high-risk BCR patients.
Professor Ng Chi Fai: New Advances in Adjuvant Therapy for Renal Cell Carcinoma and Optimization of Clinical Decision-Making | 15th Shanghai Academic Conference on Urologic Oncology

Professor Ng Chi Fai: New Advances in Adjuvant Therapy for Renal Cell Carcinoma and Optimization of Clinical Decision-Making | 15th Shanghai Academic Conference on Urologic Oncology

2026.01.12
For many years, adjuvant therapy for renal cell carcinoma (RCC) remained in a state of “therapeutic vacuum.” RCC is intrinsically resistant to radiotherapy and chemotherapy, and early attempts to introduce targeted therapies into the adjuvant setting failed to deliver meaningful benefits. The success of the KEYNOTE-564 trial has been a turning point—ushering RCC adjuvant therapy into the era of immunotherapy and redefining postoperative management for high-risk patients.
Voice of China at ASH |Professor Wang Hui / Wang Dongchu: From MRD Monitoring to Early CRS Identification—Unlocking New Paradigms in Immunologic Diagnosis and Therapy

Voice of China at ASH |Professor Wang Hui / Wang Dongchu: From MRD Monitoring to Early CRS Identification—Unlocking New Paradigms in Immunologic Diagnosis and Therapy

2026.01.11
From December 6 to 10, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. The meeting highlighted the latest advances in both clinical hematology and basic research, driving progress in the diagnosis and treatment of hematologic diseases as well as translational research.In this issue, we feature the research achievements of Professor Wang Hui’s team, covering cutting-edge technologies such as 16-color full-spectrum flow cytometry, a weighted cytokine scoring system, and other innovative approaches. These studies provide solid scientific evidence for early precise diagnosis, treatment response assessment, and timely clinical intervention, demonstrating the critical role of technological innovation in modern hematology. We warmly invite readers to engage in further discussion and exchange.
Voice of China at ASH | Professor Wang Huafeng: Reconstructing Survival Prediction in Acute Myeloid Leukemia Through Multi-Omics Decoupling and Fusion

Voice of China at ASH | Professor Wang Huafeng: Reconstructing Survival Prediction in Acute Myeloid Leukemia Through Multi-Omics Decoupling and Fusion

2026.01.11
The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA, from December 6 to 9, 2025, bringing together the latest research advances and clinical progress in hematology worldwide. At this year’s meeting, Professor Wang Huafeng’s team from The First Affiliated Hospital, Zhejiang University School of Medicine had six studies accepted, including one oral presentation and five poster presentations, with one poster receiving the ASH Outstanding Abstract Award. These achievements highlight the growing international academic influence of Chinese researchers in the field of acute leukemia.